Circulating CD14⁺⁺CD16⁺ Monocyte Subsets as a Surrogate Marker of the Therapeutic Effect of Corticosteroid Therapy in Patients With Cardiac Sarcoidosis
-
- Orii Makoto
- Department of Cardiovascular Medicine, Wakayama Medical University
-
- Imanishi Toshio
- Department of Cardiovascular Medicine, Wakayama Medical University
-
- Teraguchi Ikuko
- Department of Cardiovascular Medicine, Wakayama Medical University
-
- Nishiguchi Tsuyoshi
- Department of Cardiovascular Medicine, Wakayama Medical University
-
- Shiono Yasutsugu
- Department of Cardiovascular Medicine, Wakayama Medical University
-
- Yamano Takashi
- Department of Cardiovascular Medicine, Wakayama Medical University
-
- Ino Yasushi
- Department of Cardiovascular Medicine, Wakayama Medical University
-
- Hirata Kumiko
- Department of Cardiovascular Medicine, Wakayama Medical University
-
- Kubo Takashi
- Department of Cardiovascular Medicine, Wakayama Medical University
-
- Tanaka Atsushi
- Department of Cardiovascular Medicine, Wakayama Medical University
-
- Akasaka Takashi
- Department of Cardiovascular Medicine, Wakayama Medical University
書誌事項
- タイトル別名
-
- Circulating CD14<sup>++</sup>CD16<sup>+</sup> Monocyte Subsets as a Surrogate Marker of the Therapeutic Effect of Corticosteroid Therapy in Patients With Cardiac Sarcoidosis
この論文をさがす
抄録
Background:We aimed to evaluate whether specific monocyte subsets could serve as surrogate markers of disease activity in cardiac sarcoidosis (CS) evaluated by 18F-fluoro-2-deoxyglucose positron emission tomography (18F-FDG PET).Methods and Results:We studied 28 patients with CS (8 men; mean age: 61±9 years) diagnosed according to consensus criteria. We divided the patients into 2 groups: known CS receiving corticosteroid therapy (Rx(+); n=13) and new-onset CS (Rx(−); n=15), and analyzed 3 distinct monocyte subsets (CD14+CD16−, CD14++CD16+, and CD14+−CD16+). Monocyte subsets were also analyzed in 10 Rx(−) patients before and 12 weeks after starting corticosteroid therapy. Inflammatory activity was quantified by 18F-FDG PET using the coefficient of variation (COV) of the standardized uptake value (SUV). The proportion of CD14++CD16+monocytes in Rx(+) patients (10.8 [0.2–23.5] %) was significantly lower than in Rx(−) patients (23.0 [11.5–38.4] %, P=0.001). After corticosteroid therapy, the COV of the SUV was significantly improved from 0.32 [0.14–0.62] to 0.17 [0.04–0.43] (P=0.017). The proportion of CD14++16+monocytes showed a significant decrease from 22.2 [8.8–38.4] % to 8.4 [1.8–16.8] % (P=0.001). The decrease in the proportion of CD14++16+monocytes significantly correlated with the decrease in the COV of the SUV (r=0.495, P=0.027).Conclusions:CD14++16+monocytes are a possible surrogate marker of the therapeutic effect of corticosteroid therapy in CS. (Circ J 2015; 79: 1585–1592)
収録刊行物
-
- Circulation Journal
-
Circulation Journal 79 (7), 1585-1592, 2015
一般社団法人 日本循環器学会
- Tweet
キーワード
詳細情報 詳細情報について
-
- CRID
- 1390001205106918912
-
- NII論文ID
- 130005083931
-
- NII書誌ID
- AA11591968
-
- ISSN
- 13474820
- 13469843
-
- NDL書誌ID
- 026523728
-
- PubMed
- 25833081
-
- 本文言語コード
- en
-
- データソース種別
-
- JaLC
- NDL
- Crossref
- PubMed
- CiNii Articles
- KAKEN
-
- 抄録ライセンスフラグ
- 使用不可